VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-alpha, IL-1beta, IL-10. VGX-1027 has antidiabetogenic effects by limiting cytokine-mediated immunoinflammatory events[1][2][3].
Molekulargewicht:
205.21
Reinheit:
99.67
CAS Nummer:
[6501-72-0]
Formel:
C11H11NO3
Target-Kategorie:
Interleukin Related,TNF Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten